Ancillary Studies. As HOMAGE was getting presented by the partners, we gained interest by several groups to collaborate and extend the efforts of HOMAGE. These collaborations, performed within HOMAGE, presented below, are promising and will allow to complete our understanding of the disease and study population with different phenotype and co-morbidities:
Ancillary Studies. Each Party hereby grants to the other Party a Right of Reference to, and will promptly disclose to such other Party upon such other Party’s request, certain Data generated in any completed Ancillary Studies [***], as further provided in Section 6.5 (Rights of Reference).
Ancillary Studies. If the Research Project does not involve collaboration with SPIROMICS and/or SOURCE Investigators, then the Recipient agrees to, in accordance with Section 6 (Publication), include the following language in an acknowledgment. "The Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is funded by contract from the National Heart, Lung, and Blood Institute (NHLBI) (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN2682009000019C, HHSN268200900020C, U01 HL137880, U24 HL141762, and R01 HL182622). “SPIROMICS Study of Early COPD Progression (SOURCE) is funded by the National Heart, Lung, and Blood Institute (NHLBI) (R01 HL144718). This manuscript was not prepared in collaboration with investigators of the SOURCE Study and does not necessarily reflect the opinions or conclusions of SOURCE or the NHLBI.” “This manuscript was not prepared in collaboration with investigators of the SPIROMICS Study and does not necessarily reflect the opinions or conclusions of SPIROMICS or the NHLBI.”
Ancillary Studies. If the Research Project does not involve collaboration with SPIROMICS and/or SOURCE Investigators, then the Recipient agrees to, in accordance with Section 5 (Publication), include the following language in an acknowledgment. "The Subpopulations and Intermediate Outcomes in COPD Study (SPIROMICS) is funded by contract from the National Heart, Lung, and Blood Institute (NHLBI) (HHSN268200900013C, HHSN268200900014C, HHSN268200900015C, HHSN268200900016C, HHSN268200900017C, HHSN268200900018C, HHSN2682009000019C, HHSN268200900020C, U01 HL137880, U24 HL141762, and R01 HL182622).
